Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Tuesday, August 08, 2017 12:06:24 PM
- Fundamental value drivers of InMed Pharmaceuticals are its drug development pipeline and proprietary biosynthesis technology in cannabinoid manufacturing
- Biopharmaceutical company already has two drug candidates – INM-085 and INM-750 – in the multi-billion dollar ocular and dermatology markets
- INM-085 and INM-750 target markets valued in excess of $5 billion and $1 billion, respectively
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed. It may eventually lead to a product which encompasses cannabinoid compounds targeting pain-related receptors in the body.
InMed is a Vancouver-based preclinical stage biopharmaceutical company specializing in the development of cannabinoid-based therapies using novel drug therapies and delivery systems. Value drivers for the company are its proprietary process for cannabinoid manufacturing and its drug candidate pipeline. It already has two preclinical product candidates. INM-085 has been developed for the treatment of glaucoma, an eye disease that accounts for a greater than $5 billion global market. The other is INM-750 for the treatment of orphan disease epidermolysis bullosa (EB), which is characterized by fragile skin. There are no approved therapies for the disease in this $1 billion market.
The InMed Pharmaceuticals article in the Journal (http://nnw.fm/3o95X) focuses on how THC impacts the peripheral cannabinoid (CB) receptors CB1 and CB2. The results are that THC activates the CB1 receptor to provide analgesic relief without side effects. The study results suggest that THC could provide a novel approach to offer that relief through the peripheral application of cannabinoids.
The article is titled, “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation.” The study was co-funded by Canadian non-profit organization Mitacs and InMed Pharmaceuticals. In a news release, Hossain, co-author of the findings report, said, “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”
The result could be a valuable approach in the cannabinoid treatment of severe pain. The model used in this study mimics the muscle pain of temporomandibular joint disorders (TMD) that affect the jaw muscle. TMD is a chronic pain condition that’s difficult to treat.
For more information, visit the company’s website at www.InMedPharma.com
Recent INM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 08:20:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 08:20:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 08:20:23 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 08:27:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 06:38:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 07:58:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 10:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 05:34:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 07:33:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 07:12:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:09:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:09:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:08:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:07:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:07:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:05:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:04:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 06:04:18 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 12/21/2023 10:21:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 02:02:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 07:50:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/14/2023 05:15:29 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/13/2023 10:05:08 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/08/2023 10:05:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM